The Exosome Supply Engine
Building the Supply Engine for Exosome Medicine and Aesthetic Markets
Naive Exosomes
Commercial Products and Therapeutic Building Blocks
Naïve exosomes are natural biological nanoparticles produced by cells. They play a role in cellular communication, immune modulation, and regenerative signaling.
For commercial markets, their natural properties may support applications in regenerative aesthetics and other non-drug categories where interest is growing in cell-free, biology-based products associated with skin quality, tissue support, and healthy aging.
For NurExone’s therapeutic pipeline, naïve exosomes serve as the biological starting point for the Company’s ExoTherapy platform. NurExone applies proprietary loading technology to repurpose these natural nanoparticles as drug delivery vehicles, adding defined therapeutic cargo and transforming them into targeted exosome-based nanodrugs.
Powering Medicine & Aesthetics
The ExoTop Value Engine
Exo-Top was established to allow NurExone to control a critical foundation in the exosome field – reliable, scalable supply of natural MSC-derived naïve exosomes.
The company is built around a proprietary Master Cell Bank and the implementation of a U.S.-based manufacturing strategy designed to support batch-to-batch consistency, scalable exosome production, and GMP-based clinical and commercial supply.
This foundation may support two value pathways:
- Starting material for NurExone’s therapeutic pipeline, where exosomes can be loaded with defined therapeutic cargo to create exosome-based nanodrugs and
- Standalone naïve exosome products for regenerative aesthetics and other non-drug markets.
Commercial sales are targeted to begin in 2027 through a robust distribution network.
the Commercial Opportunity
Naive Exosomes for Regenerative Treatments and Aesthetics
Regenerative aesthetics is becoming part of a broader shift in wellness and aesthetic care: consumers, clinics, and commercial partners are increasingly looking beyond surface-level products toward biology-based approaches associated with skin quality, anti-aging, healthy aging, and regenerative treatments.
This shift creates potential commercial relevance for natural MSC-derived exosomes. In beauty and personal care, exosomes may align with demand for products focused on skin quality and youthful appearance. In spas, clinics, and aesthetic treatment settings, interest is increasingly connected to post-procedure care, tissue support, recovery-oriented protocols, and regenerative-looking outcomes. In longevity and healthy aging, the same focus on cellular-level biology creates a broader future opportunity for exosome-based applications.
Exo-Top is focused on natural MSC-derived exosomes: cell-free biological nanoparticles produced by mesenchymal stem cells. These are not plant-derived vesicles, synthetic particles, or genetically modified exosomes.
Their cellular-level biological relevance positions them within commercial categories moving toward regenerative, biology-based, anti-aging, and healthy-aging applications.
Master Cell Bank
Reproducibility and Scale
Exosome quality begins at the cell source.
Exo-Top’s strategy is built around a proprietary Master Cell Bank of mesenchymal stem cells, intended to provide a consistent starting material for exosome production. In a field where reproducibility, characterization, and batch-to-batch consistency are major barriers to scale, the Master Cell Bank is a strategic asset.
This is a core biomanufacturing advantage: a controlled source to support quality-oriented production for both commercial products and therapeutic
development.
Disclaimer: This page is for informational and investor-relations purposes only. References to aesthetic, wellness, regenerative, non-drug, commercial, or therapeutic opportunities are forward-looking and subject to regulatory, development, manufacturing, market, and commercial risks. Exo-Top products and NurExone therapeutic candidates have not been approved by any regulatory authority for the diagnosis, treatment, cure, mitigation, or prevention of any disease unless expressly stated otherwise by the Company.